Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 ...

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with ...

Amini: I believe this is critical for all stages of NSCLC. Whether you are in a small rural practice, large community or academic setting, having a team that you can communicate with is critical.

TRIANA Biomedicines Announces First Patient Dosed in a Phase 1/2 Trial Evaluating TRI-611 for the Treatment of ALK+ Non-small Cell Lung Cancer ...

The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...

Amini: This varies quite a bit by stage — operable vs. nonoperable — and patients’ performance status and preference. Additionally, more relevant to medical oncology but equally, if not more, ...

Immutep will discontinue a phase three study of its efti drug to treat first-line non-small cell lung cancer following a futility analysis. "We are very disappointed and surprised with the outcome of ...

The new €3.2M (US$3.7M) research lab will investigate immunogenic cell death mechanisms in lung cancer to improve how existing therapies trigger immune response.

Dr. Reddy's Laboratories Limited has informed stock exchanges that the Phase III clinical trial evaluating the drug candidate ...

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...

Sydney, Australia Monday, March 16, 2026, 10:00 Hrs [IST] ...

Study to test RC220 alongside standard-of-care osimertinib to prevent or delay treatment resistance. ... Read More The post ...